Mikko Lemola
NeOnc Technologies (NTHI) has decided to set its sights higher by upsizing its proposed initial public offering (IPO) to $75M from $50M.
In a recent statement to the Securities and Exchange Commission (SEC), the brain cancer therapy developer expressed its intention to elevate the fundraising target from $50M to $75M. However, specific terms were not disclosed.
NeOnc aims to list its shares on Nasdaq under the symbol NTHI. Sole bookrunner is Loop Capital Markets, with Maxim Group and Brookline Capital Markets serving as co-managers.
Headquartered in Los Angeles, NeOnc’s lead product candidate, NEO100, is currently undergoing Phase 2 testing for the treatment of recurrent malignant glioma with IDH1 mutation and meningioma. The product is also under evaluation as a drug delivery vehicle.
Exploring NeOnc Technologies Holdings, Inc. Further
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
